certain parts of what is now in the ACA, but maybe in the worst way,??? said Cohen, citing provisions on biosimilars and the omnipresent threat of price controls. ???Absent the massive, multi-factoral ACA we have now, there is going to be huge pressure to control costs, and there is a risk we will see cherry-picking, only resurrecting those aspects that are negative.???